SCHEMBL5356604

SCHEMBL5356604

CN(CCc1ccc(F)cc1)S(=O)(=O)c1ccsc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
FABP4 P15090 5/20 0.42
TAAR1 Q96RJ0 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
AOC3 Q16853 1/20 0.40
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
MCHR1 Q99705 1/20 0.38
TAS2R14 Q9NYV8 2/20 0.37
F10 P00742 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
FABP3 P05413 1/20 0.37
FABP2 P12104 1/20 0.37
FABP5 Q01469 1/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5356350 0.87 LMNA (0.54) LMNAMAPTSMN1; SMN2
SCHEMBL5361944 0.78 AOC3 (0.45) LMNAFABP4NPSR1AOC3MAPT
SCHEMBL5349250 0.78 KCNQ4 (0.39) LMNATAAR1AOC3MAPTSMN1; SMN2
SCHEMBL5356271 0.76 TAAR1 (0.50) LMNAFABP4TAAR1NPSR1SMN1; SMN2
SCHEMBL5356280 0.74 KMT2A (0.51) LMNAFABP4NPSR1MAPTFABP3
SCHEMBL5352376 0.72 LMNA (0.38) LMNAFABP4NPSR1AOC3MAPT
SCHEMBL5347924 0.70 KMT2A (0.47) TAAR1AOC3MAPTSMN1; SMN2KDM4E
SCHEMBL13184563 0.70 TAAR1 (0.60) LMNATAAR1AOC3MAPTSMN1; SMN2
SCHEMBL18090577 0.70 ALDH1A1 (0.44) LMNANPSR1SMN1; SMN2KDM4EMEN1
SCHEMBL12133653 0.70 SMN1; SMN2 (0.64) LMNATAAR1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 LMNA 4744/4885FABP4 2812/4885TAAR1 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.